Exchange: NYSE·Updated 02:36 PM EDT

WST News

News
all
press releases
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.
Zacks
More News
Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC
PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.
Zacks
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
Zacks
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Zacks
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
VEEV's strong Q2 results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
Zacks
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.
Zacks
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
Zacks
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
Zacks
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.
Zacks
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
Zacks

Advertisement|Remove ads.